Response to Therapy of 26 Patients With Large-Cell Transformation
| Patient No. . | Stage at Transformation . | Initial Therapy After Transformation* . | Response to Therapy . | Response Duration (mo) . | Survival After Transformation (mo) . | Previous Chemotherapy . | Patient Status . |
|---|---|---|---|---|---|---|---|
| 1 | IB | Comb. modal. 1† | CR | 14+ | 32+ | No | NED |
| 2 | IIB | Comb. modal. 2‡ | CR | 42+ | 51+ | No | NED |
| 3 | IIIA | Photopheresis | PR | 11 | 22+ | Yes | AWD |
| 4 | IIA | Comb. modal. 1 | CR | 55+ | 82+ | No | NED |
| 5 | IB | PUVA | PR | 14+ | 26+ | No | AWD |
| 6 | IB | Photopheresis | PR | 8 | 29+ | No | AWD |
| 7 | IIA | Comb. modal. 1 | CR | 7+ | 15+ | No | NED |
| 8 | IIB | DCF | PR | 7 | 34+ | No | AWD |
| 9 | IIB | XRT | PR | 6 | 21 | Yes | DOD |
| 10 | IIB | XRT | PR | 1 | 4 | Yes | DOD |
| 11 | IIB | IFN + Accutane | NR | 0 | 6 | No | DOD |
| 12 | IVA | CVP | PR | 2 | 22 | No | DOD |
| 13 | IVA | Comb. modal. 2 | NR | 0 | 11 | No | DOD |
| 14 | IVA | TBEB | PR | 12 | 13 | Yes | DOC |
| 15 | IIB | CHOP + BLEO | NR | 0 | 25 | No | DOD |
| 16 | IIB | Photopheresis | NR | 0 | 12 | Yes | DOD |
| 17 | IIIA | H65MoAb | PR | 4 | 16 | Yes | DOD |
| 18 | IVA | XRT + IFN + NM | PR | 12 | 20 | Yes | DOD |
| 19 | IVB | IFN + Accutane | NR | 0 | 17 | No | DOD |
| 20 | IIB | Comb. modal. 2 | CR | 2 | 7 | No | DOC |
| 21 | IIB | XRT | NR | 0 | 4 | Yes | DOD |
| 22 | IIB | CHOP + BLEO | PR | 4 | 10 | No | DOD |
| 23 | IB | NM | PR | 5 | 13 | No | DOD |
| 24 | IIA | TBEB | MR | 7 | 138 | No | DOD |
| 25 | IVB | CMED | PR | 1+ | 2+ | No | AWD |
| 26 | IVA | Photopheresis | PR | 1+ | 2+ | No | AWD |
| Patient No. . | Stage at Transformation . | Initial Therapy After Transformation* . | Response to Therapy . | Response Duration (mo) . | Survival After Transformation (mo) . | Previous Chemotherapy . | Patient Status . |
|---|---|---|---|---|---|---|---|
| 1 | IB | Comb. modal. 1† | CR | 14+ | 32+ | No | NED |
| 2 | IIB | Comb. modal. 2‡ | CR | 42+ | 51+ | No | NED |
| 3 | IIIA | Photopheresis | PR | 11 | 22+ | Yes | AWD |
| 4 | IIA | Comb. modal. 1 | CR | 55+ | 82+ | No | NED |
| 5 | IB | PUVA | PR | 14+ | 26+ | No | AWD |
| 6 | IB | Photopheresis | PR | 8 | 29+ | No | AWD |
| 7 | IIA | Comb. modal. 1 | CR | 7+ | 15+ | No | NED |
| 8 | IIB | DCF | PR | 7 | 34+ | No | AWD |
| 9 | IIB | XRT | PR | 6 | 21 | Yes | DOD |
| 10 | IIB | XRT | PR | 1 | 4 | Yes | DOD |
| 11 | IIB | IFN + Accutane | NR | 0 | 6 | No | DOD |
| 12 | IVA | CVP | PR | 2 | 22 | No | DOD |
| 13 | IVA | Comb. modal. 2 | NR | 0 | 11 | No | DOD |
| 14 | IVA | TBEB | PR | 12 | 13 | Yes | DOC |
| 15 | IIB | CHOP + BLEO | NR | 0 | 25 | No | DOD |
| 16 | IIB | Photopheresis | NR | 0 | 12 | Yes | DOD |
| 17 | IIIA | H65MoAb | PR | 4 | 16 | Yes | DOD |
| 18 | IVA | XRT + IFN + NM | PR | 12 | 20 | Yes | DOD |
| 19 | IVB | IFN + Accutane | NR | 0 | 17 | No | DOD |
| 20 | IIB | Comb. modal. 2 | CR | 2 | 7 | No | DOC |
| 21 | IIB | XRT | NR | 0 | 4 | Yes | DOD |
| 22 | IIB | CHOP + BLEO | PR | 4 | 10 | No | DOD |
| 23 | IB | NM | PR | 5 | 13 | No | DOD |
| 24 | IIA | TBEB | MR | 7 | 138 | No | DOD |
| 25 | IVB | CMED | PR | 1+ | 2+ | No | AWD |
| 26 | IVA | Photopheresis | PR | 1+ | 2+ | No | AWD |
Abbreviations: AWD, alive with disease; BLEO, bleomycin; CHOP, cyclophosphamide, adriamycin, vincristine, prednisone; CMED, cyclophosphamide, methotrexate, etoposide, decadron; comb. modal, combined modality; CVP, cyclophosphamide, vincristine, prednisone; CR, complete response; DCF, deoxycoformycin; DOC, dead of other causes; DOD, dead of disease; Dx, diagnosis; H65MoAb, anti-CD5 antibody coupled to the ricin A chain toxin (H65-RTA); IFN, interferon; MR, mixed response; NED, no evidence of disease; NM, nitrogen mustard; NR, no response; PR, partial response; PUVA, psoralen (8-methoxypsoralen) and UVA light; XRT, local radiation.
First regimen after transformation.
Combined modality 1 = interferon-α + cis-retinoid acid, followed by TBEB, followed by interferon-α and topical nitrogen mustard maintenance (stages I-II).
Combined modality 2 = interferon-α and cis-retinoic acid followed by multiagent chemotherapy, followed by TBEB, followed by interferon-α and topical nitrogen mustard maintenance (stage III-IV).23